Changes in mononuclear cell subsets in capillary and venous blood of patients with psoriasis depending on the treatment

S. V. Sennikova, A. Toptygina
{"title":"Changes in mononuclear cell subsets in capillary and venous blood of patients with psoriasis depending on the treatment","authors":"S. V. Sennikova, A. Toptygina","doi":"10.46235/1028-7221-1159-cim","DOIUrl":null,"url":null,"abstract":"Topical glucocorticoids are conventionally used to treat psoriasis, but such treatment provides a short-term effect, and may cause various complications during long-term usage. A detailed study of the immunopathogenesis of psoriasis has made it possible to use bioengineered drugs that block the main cytokines. It has been shown that IL-36 plays an important regulatory role in pathogenesis of psoriasis. The aim of the study was to study therapeutic effect of patients with psoriasis using topical glucocorticoid hormone versus IL- 36 receptor antagonist (RAIL-36), with respect to clinical course of psoriasis and the subsets of mononuclear cells in venous and capillary blood taken close to the focus of inflammation. 16 patients with psoriasis (group 1a) received 0.1% mometasone cream for 14 days; 20 patients of group 1b received a gel containing 0.4% recombinant RAIL-36 for 14 days. Control group included 20 healthy adults. Treatment efficacy was assessed by PASI, DISHS and DLQI indices. 19 lymphocyte subsets and 3 monocyte subsets were assessed by four-color staining of whole capillary and venous blood with erythrocyte lysis using BD Biosciences (USA) technologies and reagents. It was shown that both drugs led to a decrease in the severity of the disease at the end of treatment. However, 2 weeks after the end of treatment in group 1a, the disease indexes nearly returned to the initial values. Meanwhile, the reduced index levels persisted 2 weeks later in group 1b. Significant deviations (more pronounced in capillary blood) were revealed for the levels of several leukocyte subsets in the psoriasis patients compared with healthy persons. As a result of treatment, we have revealed some changes in the levels of leukocyte subsets common to the two groups, and special differences for the two treatment options, that were more pronounced in capillary blood samples. Both medical preparations used are suitable for treatment of psoriasis.","PeriodicalId":21524,"journal":{"name":"Russian Journal of Immunology","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46235/1028-7221-1159-cim","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Topical glucocorticoids are conventionally used to treat psoriasis, but such treatment provides a short-term effect, and may cause various complications during long-term usage. A detailed study of the immunopathogenesis of psoriasis has made it possible to use bioengineered drugs that block the main cytokines. It has been shown that IL-36 plays an important regulatory role in pathogenesis of psoriasis. The aim of the study was to study therapeutic effect of patients with psoriasis using topical glucocorticoid hormone versus IL- 36 receptor antagonist (RAIL-36), with respect to clinical course of psoriasis and the subsets of mononuclear cells in venous and capillary blood taken close to the focus of inflammation. 16 patients with psoriasis (group 1a) received 0.1% mometasone cream for 14 days; 20 patients of group 1b received a gel containing 0.4% recombinant RAIL-36 for 14 days. Control group included 20 healthy adults. Treatment efficacy was assessed by PASI, DISHS and DLQI indices. 19 lymphocyte subsets and 3 monocyte subsets were assessed by four-color staining of whole capillary and venous blood with erythrocyte lysis using BD Biosciences (USA) technologies and reagents. It was shown that both drugs led to a decrease in the severity of the disease at the end of treatment. However, 2 weeks after the end of treatment in group 1a, the disease indexes nearly returned to the initial values. Meanwhile, the reduced index levels persisted 2 weeks later in group 1b. Significant deviations (more pronounced in capillary blood) were revealed for the levels of several leukocyte subsets in the psoriasis patients compared with healthy persons. As a result of treatment, we have revealed some changes in the levels of leukocyte subsets common to the two groups, and special differences for the two treatment options, that were more pronounced in capillary blood samples. Both medical preparations used are suitable for treatment of psoriasis.
银屑病患者毛细血管和静脉血中单核细胞亚群随治疗的变化
局部糖皮质激素通常用于治疗牛皮癣,但这种治疗提供短期效果,并可能在长期使用中引起各种并发症。对银屑病免疫发病机制的详细研究使得使用阻断主要细胞因子的生物工程药物成为可能。研究表明,IL-36在银屑病的发病过程中起着重要的调节作用。本研究的目的是研究外用糖皮质激素与IL-36受体拮抗剂(RAIL-36)对银屑病患者的治疗效果,以及银屑病的临床病程和炎症病灶附近静脉和毛细血管血中单个核细胞亚群的变化。16例银屑病患者(1a组)接受0.1%莫米松乳膏治疗,疗程14 d;1b组20例患者接受含有0.4%重组RAIL-36的凝胶治疗,持续14天。对照组为健康成人20例。采用PASI、dish、DLQI指标评价治疗效果。采用美国BD Biosciences公司的技术和试剂,采用红细胞溶解法对全毛细血管和静脉血进行四色染色,测定19个淋巴细胞亚群和3个单核细胞亚群。研究表明,这两种药物在治疗结束时都能降低疾病的严重程度。然而,在1a组治疗结束2周后,疾病指标几乎恢复到初始值。与此同时,1b组的指数下降水平在2周后持续存在。与健康人相比,银屑病患者的几种白细胞亚群水平存在显著差异(在毛细血管血液中更为明显)。作为治疗的结果,我们揭示了两组共同的白细胞亚群水平的一些变化,以及两种治疗方案的特殊差异,这在毛细血管血液样本中更为明显。所使用的两种药物制剂均适用于治疗牛皮癣。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信